Overview

Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants

Status:
Not yet recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of VX-548 and its metabolite in the absence and presence of omeprazole or rifampin, in healthy participants.

Phase:

Phase 1

Details

Lead Sponsor:

Vertex Pharmaceuticals Incorporated

Treatments:

Omeprazole
Rifampin